Intravitreal methotrexate as adjunctive, palliative therapy in intraocular T-cell lymphoma.
OBJECTIVE
To report on the rapid and sustained effect following injection of intravitreal methotrexate (IVTMTX) in intraocular T-cell lymphoma.


METHODS
Report of 2 cases.


METHODS
A young male with natural killer/T-cell lymphoma presented with infiltrative nodular iridocyclitis and received a single IVTMTX. An elderly female with peripheral T-cell lymphoma presented with a hypopyon, infiltrative iridocyclitis, and choroidal effusions and received 3 IVTMTX over 4 months.


RESULTS
Both patients responded well after the first injection, with resolution of signs within 1 week and improvement in vision.


CONCLUSIONS
IVTMTX may be effective as a palliative, vision-restoring measure in patients with systemic T-cell lymphoma.
Wickremasinghe
Sanjeewa S
SS
The Ocular Immunology Clinic, The Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Ojaimi
Elvis
E
Lim
Lyndell
L
Stawell
Richard
R
McKelvie
Penelope
P
Zamir
Ehud
E
D000328:Adult; D000369:Aged, 80 and over; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D058449:Intravitreal Injections; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D010166:Palliative Care / Q000379:methods*; D041623:Tomography, Optical Coherence
D007166:Immunosuppressive Agents; D008727:Methotrexate